Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: A cross-sectional study

Das, Hrishov; Banik, Sujan

doi:10.1016/j.dsx.2018.09.006

Cited by 33 publications

(36 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T2D and its interconnected metabolic complications such as obesity are of clinical significance because of their epidemic prevalence and contribution to the rapid rise of noncommunicable‐related deaths . Dyslipidaemia remains the major characteristic feature of T2D, and its prevalence among diabetic patients may be high as 70% in some populations . Even worse, enhanced lipid deposits on the arterial wall in patients presenting with dyslipidaemia have been associated with the development and worsening of atherosclerosis .…”

Section: Discussionmentioning

confidence: 99%

The impact of coenzyme Q₁₀ on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials

Dludla

Nyambuya

Orlando

et al. 2020

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

Aims: Coenzyme Q 10 (CoQ10) is well known for its beneficial effects in cardiovascular disease (CVD); however, reported evidence has not been precisely synthesized to better inform on its impact in protecting against cardiovascular-related complications in diabetic patients. Materials and Methodology:The current meta-analysis included randomized controlled trials published in the past 5 years reporting on the effect of CoQ10 on metabolic and CVD-related risk profiles in individuals with diabetes or metabolic syndrome.We searched electronic databases such as MEDLINE, Cochrane Library, Scopus and EMBASE for eligible studies. In addition to assessing the risk of bias and quality of evidence, the random and fixed-effect models were used to calculate the standardized mean difference and 95% confidence intervals for metabolic parameters and CVD outcomes. Results:Overall, 12 studies met the inclusion criteria, enrolling a total of 650 patients.Although CoQ10 supplementation did not statistically affect all metabolic profiles measured, it significantly reduced CVD-risk-related indexes such as total cholesterol and low-density lipoprotein (LDL) levels in diabetic patients when compared to those on placebo [SMD = 0.13, 95% CI (0.03; 0.23), Chi 2 = 43.62 and I 2 = 29%, P = .07]. Conclusions: The overall results demonstrated that supplementation with CoQ10shows an enhanced potential to lower CVD risk in diabetic patients by reducing total cholesterol and LDL. Moreover, the beneficial effects of CoQ10 in lowering the CVD risk are associated with its ameliorative properties against oxidative stress and improving endothelial health.

show abstract

Section: Discussionmentioning

confidence: 99%

The impact of coenzyme Q₁₀ on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials

Dludla

Nyambuya

Orlando

et al. 2020

Endocrino Diabet & Metabol

View full text Add to dashboard Cite

show abstract

“…Complex pathological mechanisms have thus far been linked with the development and aggravation of metabolic syndrome. For instance, a state of dyslipidemia, which is characterized by abnormally elevated serum levels of triglycerides and cholesterol, has been shown to promote enhanced ectopic lipid accumulation and subsequent injury to various body organs [4,11,12]. Increased organ and arterial lipid accumulation can induce insulin resistance and cause endothelial dysfunction, mostly through exacerbating inflammation and oxidative stress.…”

Section: Introductionmentioning

confidence: 99%

Coenzyme Q10 Supplementation Improves Adipokine Levels and Alleviates Inflammation and Lipid Peroxidation in Conditions of Metabolic Syndrome: A Meta-Analysis of Randomized Controlled Trials

Dludla

Orlando

Silvestri

et al. 2020

IJMS

View full text Add to dashboard Cite

Evidence from randomized controlled trials (RCTs) suggests that coenzyme Q10 (CoQ10) can regulate adipokine levels to impact inflammation and oxidative stress in conditions of metabolic syndrome. Here, prominent electronic databases such as MEDLINE, Cochrane Library, and EMBASE were searched for eligible RCTs reporting on any correlation between adipokine levels and modulation of inflammation and oxidative stress in individuals with metabolic syndrome taking CoQ10. The risk of bias was assessed using the modified Black and Downs checklist, while the Grading of Recommendations Assessment, Development and Evaluation (GRADE) tool was used to evaluate the quality of evidence. Results from the current meta-analysis, involving 318 participants, showed that CoQ10 supplementation in individuals with metabolic syndrome increased adiponectin levels when compared to those on placebo (SMD: 1.44 [95% CI: −0.13, 3.00]; I2 = 96%, p < 0.00001). Moreover, CoQ10 supplementation significantly lowered inflammation markers in individuals with metabolic syndrome in comparison to those on placebo (SMD: −0.31 [95% CI: −0.54, −0.08]; I2 = 51%, p = 0.07). Such benefits with CoQ10 supplementation were related to its ameliorative effects on lipid peroxidation by reducing malondialdehyde levels, concomitant to improving glucose control and liver function. The overall findings suggest that optimal regulation of adipokine function is crucial for the beneficial effects of CoQ10 in improving metabolic health.

show abstract

“…In the current study mean serum cholesterol levels were significantly higher in diabetic patients (202.50 ± 42.70 mg/dl) compared to the healthy controls (163.53 ± 2.30 mg/dl). Similarly, several recent clinical studies have revealed higher mean levels of total cholesterol in type 2 diabetes mellitus patients compared to control participants (Das & Bank, 2019;Sarfraz et al, 2016). Many factors are likely to be responsible for diabetic dyslipidaemias.…”

Section: Discussionmentioning

confidence: 89%

Circulating CXCL16 in type 2 diabetes mellitus Egyptian patients

Tawfik

Abdel-Messeih

Nosseir

et al. 2021

Journal of Radiation Research and Applied Sciences

View full text Add to dashboard Cite

Background: Type 2 diabetes mellitus (T2DM) is an international health concern. The C-X-C chemokine ligand 16 (CXCL16) functions as a scavenging cell surface receptor. Vitamin D3 has vital effects on inflammation and insulin homeostasis. Purpose: To investigate the significance of serum CXCL 16 and vitamin D3 in T2DM patients to understand disease pathophysiology. Materials and Methods: The current work was performed as a cross-sectional study.The study included 60 participants, 30 patients with T2DM attending the national institute of diabetes clinics and 30 age and sex-matched healthy controls. Participants underwent the following: Serum CXCL16 by enzyme-linked immunosorbent assay (ELISA), vitaminD3 by radioimmuno assay(RIA), glycosylated hemoglobin (HbA1c), fasting blood sugar(FBS), thyroid stimulating hormone (TSH), liver and kidney functions. Results and discussion: Serum CXCL16 levels were significantly higher and serum vitamin D3 levels were significantly lower in T2DM patients compared to controls (p < 0.00001). Serum CXCL16 levels correlated negatively with vitamin D3 levels (r = -0.837 and p = 0.00001) while a negative correlation was recognized between vitaminD3 levels and HbA1c % in patients (r = −0.609 and p = 0.00035). Conclusion: Serum CXCL16, vitamin D3 and HbA1 c may be important parameters in monitoring T2DM and predicting complications.

show abstract

Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: A cross-sectional study

Cited by 33 publications

References 24 publications

The impact of coenzyme Q₁₀ on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials

The impact of coenzyme Q₁₀ on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials

Coenzyme Q10 Supplementation Improves Adipokine Levels and Alleviates Inflammation and Lipid Peroxidation in Conditions of Metabolic Syndrome: A Meta-Analysis of Randomized Controlled Trials

Circulating CXCL16 in type 2 diabetes mellitus Egyptian patients

Contact Info

Product

Resources

About

Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: A cross-sectional study

Cited by 33 publications

References 24 publications

The impact of coenzyme Q10 on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials

The impact of coenzyme Q10 on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials

Coenzyme Q10 Supplementation Improves Adipokine Levels and Alleviates Inflammation and Lipid Peroxidation in Conditions of Metabolic Syndrome: A Meta-Analysis of Randomized Controlled Trials

Circulating CXCL16 in type 2 diabetes mellitus Egyptian patients

Contact Info

Product

Resources

About

The impact of coenzyme Q₁₀ on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials

The impact of coenzyme Q₁₀ on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta‐analysis of randomized controlled trials